Changxin Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Changxin Li has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Hideki Moriyama
Life and Medical Sciences Area, Health Sciences Discipline, Kobe University, Kobe, Japan
3 shared publications Junpei Hatakeyama
Department of Rehabilitation Science, Graduate School of Health Sciences, Kobe University, Kobe, Japan
3 shared publicationsShota Inoue
Department of Rehabilitation Science, Graduate School of Health Sciences, Kobe University, Kobe, Japan
3 shared publicationsDaisuke Takamura
Department of Rehabilitation Science, Graduate School of Health Sciences, Kobe University, Kobe, Japan
2 shared publicationsHanlin Jiang
Department of Rehabilitation Science, Graduate School of Health Sciences, Kobe University, Kobe, Japan
2 shared publicationsToshihiro Akisue
Life and Medical Sciences Area, Health Sciences Discipline, Kobe University, Kobe, Japan
2 shared publications
Latest Publications
- Open Access
- 29 April 2026
- Published by MDPI AG in Pharmaceuticals
- Vol. 19 (5) , 703
From Nature to Pharmacy: A Review of Tectoridin for Modern Therapeutics
Background: Tectoridin is a prominent isoflavone glycoside found in herbs such as Belamcanda chinensis (L.) DC and Iris tectorum Maxim. It has drawn increasing research interest due to its promising pharmacological activities. However, no critical review to date has determined whether its broad pharmacological activity stems from binding to specific targets or from the non-specific, broad-spectrum activity commonly associated with flavonoids. This paper provides a comprehensive review of tectoridin, covering its plant sources, pharmacological effects, pharmacokinetics, and toxicity, alongside an in-depth analysis of the mechanisms underlying its pharmacological effects and strategic recommendations for advancing its clinical translation. Methods: A systematic literature search was conducted in PubMed, Web of Science, Google Scholar, SciFinder, and CNKI for publications from 1968 to 2025 using keywords including tectoridin, tectorigenin 7-O-glucoside, traditional uses, ethnopharmacology, pharmacology, bioactive compounds, biological activity, pharmacokinetics and toxicity. Results: Tectoridin exhibits a broad spectrum of pharmacological activities, including anticancer, anti-inflammatory, hepatoprotective, antidiabetic, antioxidant, cardiovascular, and estrogenic effects. Pharmacokinetic studies have shown rapid tissue distribution and slow elimination; the aglycone metabolite tectorigenin often displays enhanced bioactivity, and chemical modifications may further improve efficacy. Toxicity data suggest relative safety in medicinal food contexts, but comprehensive in vivo studies remain limited. Tectoridin shows promise for treating cancer and inflammatory diseases; however, further research is needed to elucidate its molecular mechanisms, clarify toxicity, and optimize bioactivity. Conclusions: This review bridges natural products and modern therapeutics by focusing on tectoridin, highlighting its therapeutic potential, addressing challenges, and offering new perspectives for treating various diseases.
- 29 April 2026
- Published by MDPI AG in Pharmaceuticals
- Vol. 19 (5) , 703
Open AccessFrom Nature to Pharmacy: A Review of Tectoridin for Modern Therapeutics
Background: Tectoridin is a prominent isoflavone glycoside found in herbs such as Belamcanda chinensis (L.) DC and Iris tectorum Maxim. It has drawn increasing research interest due to its promising pharmacological activities. However, no critical review to date has determined whether its broad pharmacological activity stems from binding to specific targets or from the non-specific, broad-spectrum activity commonly associated with flavonoids. This paper provides a comprehensive review of tectoridin, covering its plant sources, pharmacological effects, pharmacokinetics, and toxicity, alongside an in-depth analysis of the mechanisms underlying its pharmacological effects and strategic recommendations for advancing its clinical translation. Methods: A systematic literature search was conducted in PubMed, Web of Science, Google Scholar, SciFinder, and CNKI for publications from 1968 to 2025 using keywords including tectoridin, tectorigenin 7-O-glucoside, traditional uses, ethnopharmacology, pharmacology, bioactive compounds, biological activity, pharmacokinetics and toxicity. Results: Tectoridin exhibits a broad spectrum of pharmacological activities, including anticancer, anti-inflammatory, hepatoprotective, antidiabetic, antioxidant, cardiovascular, and estrogenic effects. Pharmacokinetic studies have shown rapid tissue distribution and slow elimination; the aglycone metabolite tectorigenin often displays enhanced bioactivity, and chemical modifications may further improve efficacy. Toxicity data suggest relative safety in medicinal food contexts, but comprehensive in vivo studies remain limited. Tectoridin shows promise for treating cancer and inflammatory diseases; however, further research is needed to elucidate its molecular mechanisms, clarify toxicity, and optimize bioactivity. Conclusions: This review bridges natural products and modern therapeutics by focusing on tectoridin, highlighting its therapeutic potential, addressing challenges, and offering new perspectives for treating various diseases.
- Open Access
- 22 October 2025
- Published by British Editorial Society of Bone & Joint Surgery in Bone & Joint Research
- Vol. 14 (10) , 888-900
Transcutaneous carbon dioxide improves joint inflammation and articular cartilage degeneration in rat osteoarthritis models
Aims: As global ageing and life expectancy increase, the prevalence and incidence of osteoarthritis (OA) are expected to rise. Transcutaneous carbon dioxide (CO 2 ) therapy has been shown to promote muscle regeneration, fracture healing, strengthen athletic endurance, and aid recovery from peripheral nerve damage and cancer. However, its effect on symptom modification and inflammation in OA is largely unknown. This study aimed to examine whether CO 2 therapy could slow the progression of OA and relieve OA-related inflammation in a chemically or surgically induced model in rats. Methods: OA model was induced in 32 nine-week-old male Wistar rats by intra-articular injection of monosodium iodoacetate (MIA) and surgically induced by destabilization of the medial meniscus (DMM) in the knee joint. The pathogenesis period of MIA was set at two weeks, and for DMM at four weeks. After the creation of the OA model, either CO 2 therapy or sham intervention was applied daily for 20 minutes, and treatment was applied at two weeks. Behavioural assessments were completed at the end of the intervention period, and then knee joints were harvested. Non-demineralized frozen sections were prepared, and samples were examined histologically. Results: Assessments of knee joint diameter showed that knee swelling in the DMM model improved significantly after two weeks of CO 2 therapy compared to the control group. The histomorphometric evaluation showed a significant increase in chondrocyte density in the CO 2 group compared to the MIA and DMM groups. Furthermore, the number of matrix metalloproteinase 13 (MMP13), a disintegrin and metalloproteinase with thrombospondin motifs 5 (ADAMTS5), and proinflammatory cytokines tumour necrosis factor-α (TNF-α), interleukin (IL)-1β, and IL-6 positive cells decreased in the CO 2 group. In contrast, the number of aggrecan and type II collagen-positive cells increased. Conclusion: Our results demonstrate that transcutaneous CO 2 therapy improves OA-related inflammation and suppresses the degeneration of articular cartilage. Cite this article: Bone Joint Res 2025;14(10):888–900.
- 22 October 2025
- Published by British Editorial Society of Bone & Joint Surgery in Bone & Joint Research
- Vol. 14 (10) , 888-900
Open AccessTranscutaneous carbon dioxide improves joint inflammation and articular cartilage degeneration in rat osteoarthritis models
Aims: As global ageing and life expectancy increase, the prevalence and incidence of osteoarthritis (OA) are expected to rise. Transcutaneous carbon dioxide (CO 2 ) therapy has been shown to promote muscle regeneration, fracture healing, strengthen athletic endurance, and aid recovery from peripheral nerve damage and cancer. However, its effect on symptom modification and inflammation in OA is largely unknown. This study aimed to examine whether CO 2 therapy could slow the progression of OA and relieve OA-related inflammation in a chemically or surgically induced model in rats. Methods: OA model was induced in 32 nine-week-old male Wistar rats by intra-articular injection of monosodium iodoacetate (MIA) and surgically induced by destabilization of the medial meniscus (DMM) in the knee joint. The pathogenesis period of MIA was set at two weeks, and for DMM at four weeks. After the creation of the OA model, either CO 2 therapy or sham intervention was applied daily for 20 minutes, and treatment was applied at two weeks. Behavioural assessments were completed at the end of the intervention period, and then knee joints were harvested. Non-demineralized frozen sections were prepared, and samples were examined histologically. Results: Assessments of knee joint diameter showed that knee swelling in the DMM model improved significantly after two weeks of CO 2 therapy compared to the control group. The histomorphometric evaluation showed a significant increase in chondrocyte density in the CO 2 group compared to the MIA and DMM groups. Furthermore, the number of matrix metalloproteinase 13 (MMP13), a disintegrin and metalloproteinase with thrombospondin motifs 5 (ADAMTS5), and proinflammatory cytokines tumour necrosis factor-α (TNF-α), interleukin (IL)-1β, and IL-6 positive cells decreased in the CO 2 group. In contrast, the number of aggrecan and type II collagen-positive cells increased. Conclusion: Our results demonstrate that transcutaneous CO 2 therapy improves OA-related inflammation and suppresses the degeneration of articular cartilage. Cite this article: Bone Joint Res 2025;14(10):888–900.
- 10 April 2023
- Published by Wiley in The Journal of Physiology
- Vol. 601 (10) , 1781-1795
Effects of uphill and downhill walking on post‐traumatic osteoarthritis development in mice
Using destabilization of the medial meniscus (DMM) to induce models of osteoarthritis (OA), we sought to clarify how flat, uphill and downhill walking affects OA‐related inflammation and articular cartilage degeneration. Thirty‐two male C57BL/6J mice 7 weeks old underwent DMM surgery in their right knee and sham surgery in their left knee, and were then assigned to either the no walking after DMM group or the flat, uphill or downhill walking after DMM group (n = 8/group). After creating the knee OA model, the mice in the walking groups were subjected to treadmill walking 1 day after surgery, which included walking at 12 m/min for 30 min/day, 7 days/week, at inclines of 0, 20, or −20 degrees. Knee joints were harvested at the end of the intervention period. Non‐demineralized frozen sections were prepared and samples were examined histologically. Osteoarthritis Research Society International scores were significantly decreased in both the uphill and flat‐walking groups, compared with the no‐walking group. Immunohistochemical staining showed increased levels of aggrecan and Sry‐related high‐mobility group box9; conversely, decreased levels of matrix metalloproteinase‐13 and A disintegrin and metalloproteinase with thrombospondin motifs‐5 in both the uphill and flat‐walking groups. Micro‐CT results showed a higher bone‐volume fraction in the uphill and flat‐walking groups than that in the no‐walking group. Our findings indicate that flat and uphill walking may prevent the progression of OA. image Key points: Flat and uphill treadmill walking can prevent the development of post‐traumatic osteoarthritis in mice. Flat and uphill walking increases anabolic proteins and decreases catabolic proteins and inflammatory cytokines in articular cartilage, resulting in protection against cartilage degeneration. Downhill walking increases catabolic proteins and inflammatory cytokines in cartilage, which has negative effects on articular cartilage.
- 10 April 2023
- Published by Wiley in The Journal of Physiology
- Vol. 601 (10) , 1781-1795
Effects of uphill and downhill walking on post‐traumatic osteoarthritis development in mice
Using destabilization of the medial meniscus (DMM) to induce models of osteoarthritis (OA), we sought to clarify how flat, uphill and downhill walking affects OA‐related inflammation and articular cartilage degeneration. Thirty‐two male C57BL/6J mice 7 weeks old underwent DMM surgery in their right knee and sham surgery in their left knee, and were then assigned to either the no walking after DMM group or the flat, uphill or downhill walking after DMM group (n = 8/group). After creating the knee OA model, the mice in the walking groups were subjected to treadmill walking 1 day after surgery, which included walking at 12 m/min for 30 min/day, 7 days/week, at inclines of 0, 20, or −20 degrees. Knee joints were harvested at the end of the intervention period. Non‐demineralized frozen sections were prepared and samples were examined histologically. Osteoarthritis Research Society International scores were significantly decreased in both the uphill and flat‐walking groups, compared with the no‐walking group. Immunohistochemical staining showed increased levels of aggrecan and Sry‐related high‐mobility group box9; conversely, decreased levels of matrix metalloproteinase‐13 and A disintegrin and metalloproteinase with thrombospondin motifs‐5 in both the uphill and flat‐walking groups. Micro‐CT results showed a higher bone‐volume fraction in the uphill and flat‐walking groups than that in the no‐walking group. Our findings indicate that flat and uphill walking may prevent the progression of OA. image Key points: Flat and uphill treadmill walking can prevent the development of post‐traumatic osteoarthritis in mice. Flat and uphill walking increases anabolic proteins and decreases catabolic proteins and inflammatory cytokines in articular cartilage, resulting in protection against cartilage degeneration. Downhill walking increases catabolic proteins and inflammatory cytokines in cartilage, which has negative effects on articular cartilage.
- 20 December 2020
- Published by Japanese Physical Therapy Association in Physical Therapy Research
- Vol. 23 (2) , 113-122
Transcutaneous application of carbon dioxide improves contractures after immobilization of rat knee joint
Objective: Joint contractures are a major complication following joint immobilization. However, no fully effective treatment has yet been found. Recently, carbon dioxide (CO2) therapy was developed and verified this therapeutic application in various disorders. We aimed to verify the efficacy of transcutaneous CO2 therapy for immobilization-induced joint contracture. Method: Twenty-two Wistar rats were randomly assigned to three groups: caged control, those untreated after joint immobilization, and those treated after joint immobilization. The rats were treated with CO2 for 20 min once a daily either during immobilization, (prevention) or during remobilization after immobilization (treatment). Knee extension motion was measured with a goniometer, and the muscular and articular factors responsible for contractures were calculated. We evaluated muscle fibrosis, fibrosis-related genes (collagen Type 1α1 and TGF-β1) in muscles, synovial intima's length, and fibrosis-related proteins (Type I collagen and TGF-β1) in the joint capsules. Results: CO2 therapy for prevention and treatment improved the knee extension motion. Muscular and articular factors decreased in rats of the treatment group. The muscular fibrosis of treated rats decreased in the treatment group. Although CO2 therapy did not repress the increased expression of collagen Type 1α1, the therapy decreased the expression of TGF-β1 in the treatment group. CO2 therapy for treatment improved the shortening of the synovial membrane after immobilization and decreased the immunolabeling of TGF-β1 in the joint capsules. Conclusions: CO2 therapy may prevent and treat contractures after joint immobilization, and appears to be more effective as a treatment strategy for the deterioration of contractures during remobilization.
- 20 December 2020
- Published by Japanese Physical Therapy Association in Physical Therapy Research
- Vol. 23 (2) , 113-122
Transcutaneous application of carbon dioxide improves contractures after immobilization of rat knee joint
Objective: Joint contractures are a major complication following joint immobilization. However, no fully effective treatment has yet been found. Recently, carbon dioxide (CO2) therapy was developed and verified this therapeutic application in various disorders. We aimed to verify the efficacy of transcutaneous CO2 therapy for immobilization-induced joint contracture. Method: Twenty-two Wistar rats were randomly assigned to three groups: caged control, those untreated after joint immobilization, and those treated after joint immobilization. The rats were treated with CO2 for 20 min once a daily either during immobilization, (prevention) or during remobilization after immobilization (treatment). Knee extension motion was measured with a goniometer, and the muscular and articular factors responsible for contractures were calculated. We evaluated muscle fibrosis, fibrosis-related genes (collagen Type 1α1 and TGF-β1) in muscles, synovial intima's length, and fibrosis-related proteins (Type I collagen and TGF-β1) in the joint capsules. Results: CO2 therapy for prevention and treatment improved the knee extension motion. Muscular and articular factors decreased in rats of the treatment group. The muscular fibrosis of treated rats decreased in the treatment group. Although CO2 therapy did not repress the increased expression of collagen Type 1α1, the therapy decreased the expression of TGF-β1 in the treatment group. CO2 therapy for treatment improved the shortening of the synovial membrane after immobilization and decreased the immunolabeling of TGF-β1 in the joint capsules. Conclusions: CO2 therapy may prevent and treat contractures after joint immobilization, and appears to be more effective as a treatment strategy for the deterioration of contractures during remobilization.